Burning Rock Biotech Past Earnings Performance
Past criteria checks 0/6
Burning Rock Biotech's earnings have been declining at an average annual rate of -14.6%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 9.5% per year.
Key information
-14.6%
Earnings growth rate
14.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 9.5% |
| Return on equity | -83.6% |
| Net Margin | -111.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Burning Rock Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 510 | -567 | 640 | 288 |
| 31 Mar 24 | 521 | -590 | 638 | 319 |
| 31 Dec 23 | 537 | -654 | 686 | 347 |
| 30 Sep 23 | 559 | -708 | 735 | 372 |
| 30 Jun 23 | 586 | -764 | 788 | 397 |
| 31 Mar 23 | 570 | -895 | 900 | 397 |
| 31 Dec 22 | 563 | -971 | 939 | 422 |
| 30 Sep 22 | 568 | -1,006 | 965 | 434 |
| 30 Jun 22 | 540 | -945 | 925 | 394 |
| 31 Mar 22 | 537 | -887 | 853 | 410 |
| 31 Dec 21 | 508 | -797 | 793 | 368 |
| 30 Sep 21 | 492 | -702 | 720 | 339 |
| 30 Jun 21 | 490 | -659 | 674 | 338 |
| 31 Mar 21 | 469 | -564 | 570 | 301 |
| 31 Dec 20 | 430 | -472 | 462 | 264 |
| 30 Sep 20 | 387 | -450 | 390 | 233 |
| 30 Jun 20 | 367 | -389 | 316 | 202 |
| 31 Mar 20 | 345 | -347 | 291 | 166 |
| 31 Dec 19 | 382 | -334 | 285 | 157 |
| 30 Sep 19 | 358 | -268 | 248 | 137 |
| 31 Dec 18 | 209 | -232 | 191 | 105 |
| 31 Dec 17 | 111 | -185 | 144 | 49 |
Quality Earnings: 6BU0 is currently unprofitable.
Growing Profit Margin: 6BU0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6BU0 is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.
Accelerating Growth: Unable to compare 6BU0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6BU0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: 6BU0 has a negative Return on Equity (-83.62%), as it is currently unprofitable.